This report was recently updated on April 18 2024 with the latest and most recent
market numbers
Global Skeletal Dysplasia Market Size, Trends & Analysis - Forecasts to 2026 By Type (X-linked Hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia Ossificans Progressive, Multiple Osteochondromas, and Others), By Treatment (Medication, Surgery, and Others), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
Skeletal dysplasia is a rare disease that manifests itself in over 450 different forms. It is often regarded as Osteochondrodysplasias. It has an impact on bone and cartilage formation and progression. The severity of this condition ranges from neonatal death to adult development discrepancies. Skeletal dysplasia is an uncommon condition that is impossible to diagnose. Slow development, deformities like big head, small upper arms or legs, curved bones, arthritis, or joint pain, among others, are some of the symptoms. The disease is very common in infants and early detection aids in raising consciousness. Defective genes, which are either inherited by ancestors or altered during the development of the fetus, cause this disease. Also, it is extremely challenging to identify the mutant gene. As a result, multinationals are actively investing in the research and development of therapies for this inherited disorder.
The rising emergence of congenital disorders and genetic abnormalities is a significant driving force in the skeletal dysplasia market. As per the Center for Disease Control and Prevention, birth defects affect about one of almost 33 babies in the United States per year. Thus, the rising proportion of genetic disorders aligns well with the skeletal dysplasia market growth. Additionally, increased drug discovery and research & development initiatives are projected to boost advancement in the skeletal dysplasia market. Changes in lifestyle, as well as increased intake of smoke and liquor, are significant contributors to the rise in the prevalence of skeletal dysplasia. Government schemes to address birth defects, as well as attractive insurance arrangements, are likely to drive the skeletal dysplasia market further. Nevertheless, the finite range of treatment options for skeletal dysplasia, as well as the exorbitant prices of generic drugs, are impeding the market's expansion.
The medication for skeletal dysplasia differs according to the disorder and its root cause. Development hormones are often used in the treatment of skeletal dysplasia to increase and preserve bone density, promote bone formation, and stabilize bones with medication therapy. Additionally, height gain and spinal deformities are also possible through growth hormone therapy. Since patients are increasingly opting for such surgery, thus, the skeletal dysplasia market is assumed to develop due to this surge in adoption. However, the global market's growth is hampered by a lack of knowledge of skeletal dysplasia and poor diagnosis, especially in developing countries. Nevertheless, initiatives to promote increased understanding and early detection of skeletal dysplasia, as well as technological advances drive the global skeletal dysplasia market.
Another aspect expected to propel advancement in the international market is technological innovations. Major regulatory bodies and key players are funding the invention of an effective cure for this disorder since skeletal dysplasia is now becoming more common in infants globally. Among the main factors projected to fuel demand, momentum is the emergence of innovative pipeline drugs and the commodification of novel approved drugs. Furthermore, the rising incidence of skeletal dysplasia is expected to result in the development of new and more successful medications and therapies. For instance, Gene therapy, which combines cell-based medication with allele inhibiting, is one of the innovative therapeutic alternatives available. Additionally, the SKELDYS.ORG and Fetal Medicine Foundation are digital resources that offer guidance on skeletal dysplasia identification and therapeutic methods which are helping to create high demand for the treatment of skeletal dysplasia in the global markets. Furthermore, new innovative drug therapeutics for diagnosis are expected to contribute substantially to the expansion of the national and international skeletal dysplasia market throughout the forecast period.
Depending on the type, the skeletal dysplasia market can be classified as X-linked hypophosphatemia, hypophosphatasia, achondroplasia, fibrodysplasia ossificans progressive, multiple osteochondromas, and others. Among many other types of skeletal dysplasia, the hypophosphatasia segment will continue to lead the global skeletal dysplasia market in terms of market share. The growing volume of hypophosphatasia patients, a family medical profile of hypophosphatasia, an enhanced drug portfolio, and increased monetary funding to scientists for introducing additional novel medicines for hypophosphatasia management are likely to boost the hypophosphatasia market segment throughout the forecast period. Furthermore, an improvement in exclusive approval by regulatory bodies to provide medication to patients as soon as possible is boosting this segment.
Depending on the treatment, the skeletal dysplasia market is categorized as medication, surgery, and others. Surgery will account for the largest share of the market because it is the most common therapeutic choice for conditions such as achondroplasia and HPP. One of the key factors driving segment growth is likely to be the patients' growing preference for surgeries by specialized doctors and the finite proportion of cases reported to be unsuccessful. Moreover, numerous protocols for surgery and anesthesia patients are approved by medical regulatory bodies and practiced by many specialized medical professionals to carry out skeletal dysplasia surgeries. Thus, driving growth in this segment.
As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central South America. Through the forecast period, Europe is presumed to lead the global skeletal dysplasia market in regards to market share. The region's supremacy is due to increased surgical acceptance and disorder recognition. Sales from the North American market are envisioned to rise rapidly as medical research & development strategies to create more innovative medicines ramp up. Due to the disease's reduced intensity in the Asia Pacific region, the APAC’s skeletal dysplasia market reportedly contributes to a relatively low sales volume of the overall market.
BioMarin, Amgen Inc., Merck KGaA, Regeneron, Alexion Pharmaceuticals, Inc., Clementia (Ipsen Group), Ultragenyx Pharmaceutical, Novartis AG, Eli Lilly and Company, Cipla Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Dr. Reddy's Laboratories Ltd., Celgene Corporation, and Teva Pharmaceutical Industries are few prominent players in the skeletal dysplasia market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Skeletal Dysplasia Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Treatment Overview
2.1.3 Type Overview
2.1.4 Regional Overview
Chapter 3 Skeletal Dysplasia Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Early detection of disease
3.3.1.2 Increasing Expenditure on Healthcare
3.3.2 Industry Challenges
3.3.2.1 Limited Study and Industry Participants
3.4 Prospective Growth Scenario
3.4.1 Treatment Growth Scenario
3.4.2 Type Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Skeletal Dysplasia Market, By Treatment
4.1 Treatment Outlook
4.2 Surgery
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Medication
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Others
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Skeletal Dysplasia Market, By Type
5.1 Type Outlook
5.2 Achondroplasia
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Hypophosphatasia
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 X-linked Hypophosphatemia
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
5.5 Multiple Osteochondromas
5.5.1 Market Size, By Region, 2019-2026 (USD Million)
5.6 Fibrodysplasia Ossificans Progressive
5.6.1 Market Size, By Region, 2019-2026 (USD Million)
5.7 Others
5.7.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Skeletal Dysplasia Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.3 Market Size, By Type, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.3 Market Size, By Type, 2019-2026 (USD Million)
6.3.4 Germany
6.2.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Type, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.3 Market Size, By Type, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.7.2 Market size, By Type, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Type, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.3 Market Size, By Type, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.3 Market Size, By Type, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Type, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 BioMarin
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Amgen, Inc
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Merck KGaA
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Regeneron
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Alexion Pharmaceuticals, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Clementia (Ipsen Group)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 Ultragenyx Pharmaceutical
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Novartis AG
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Cipla Inc.
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 F. Hoffmann-La Roche Ltd
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
7.13 Merck KGaA
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info Graphic Analysis
7.14 Dr. Reddy's Laboratories Ltd.
7.14.1 Company Overview
7.14.2 Financial Analysis
7.14.3 Strategic Positioning
7.14.4 Info Graphic Analysis
7.15 Celgene Corporation
7.15.1 Company Overview
7.15.2 Financial Analysis
7.15.3 Strategic Positioning
7.15.4 Info Graphic Analysis
7.16 Celgene Corporation
7.16.1 Company Overview
7.16.2 Financial Analysis
7.16.3 Strategic Positioning
7.16.4 Info Graphic Analysis
7.17 Other Companies
7.17.1 Company Overview
7.17.2 Financial Analysis
7.17.3 Strategic Positioning
7.17.4 Info Graphic Analysis
The Global Skeletal Dysplasia Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Skeletal Dysplasia Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
